N-acetylcysteine may improve residual renal function in hemodialysis patients: A pilot study

Clinical outcomes in chronic dialysis patients are highly dependent on preservation of residual renal function (RRF). N-acetylcysteine (NAC) may have a positive effect on renal function in the setting of nephrotoxic contrast media administration. In our recent study, we showed that NAC may improve RRF in peritoneal dialysis patients. The aim of the present study was to investigate the effect of NAC on RRF in patients treated with chronic hemodialysis. Prevalent chronic hemodialysis patients with a residual urine output of at least 100mL/24hours were included. The patients were administered oral NAC 1200mg twice daily for 2 weeks. Residual renal function was assessed at baseline and at the end of treatment using a midweek interdialytic urine collection for measurement of urine output and calculation of residual renal Kt/V and glomerular filtration rate (GFR). Residual GFR was measured as the mean of urea and creatinine residual renal clearance. Each patient served as his own control. Twenty patients were prospectively enrolled in the study. Administration of NAC 1200mg twice daily for 2 weeks resulted in significant improvement in RRF: urine volume increased from 320±199 to 430±232mL/24hours (P<0.01), residual renal Kt/V increased from 0.19±0.12 to 0.29±0.14 (P<0.01), and residual GFR increased from 1.6±1.6 to 2.4±2.3mL/minute/1.73m² (P<0.01). N-acetylcysteine may improve RRF in patients treated with chronic hemodialysis.